Teva Pharmaceutical Industries Restricted – Particular Name

Operator

Welcome to the Olanzapine LAI TEV-‘749 Part III SOLARIS Knowledge Presentation Convention Name. My identify is Elliot, and I will be coordinating your name right now. [Operator Instructions].

I might now like at hand over to Christopher Stevo. Please go forward.

Christopher Stevo
Senior Vice President of Investor Relations & Aggressive Intelligence

Thanks, Elliot. Good morning and good afternoon, everybody. Thanks for becoming a member of us for this name. In a second, I am going to introduce — sorry, cross you on to my colleague, Eric Hughes, who will introduce the opposite audio system. However I simply need to let you already know we’ll be making forward-looking statements throughout right now’s name, and we undertake no obligation to replace these statements after right now’s name. And you probably have any additional questions on our forward-looking statements, please see the suitable sections of our SEC filings below kinds 10-Q and 10-Ok.

And with that, my colleague, Dr. Eric Hughes, the ground is yours.

Eric Hughes
Government VP of World R&D and Chief Medical Officer

Thanks, Chris, and thanks for everybody becoming a member of right now to speak about our SOLARIS Part III information, security and efficacy that we introduced just lately on the Psych Convention in San Diego.

Shifting ahead, earlier than we get speaking about our program for schizophrenia, I did need to briefly spotlight the robust neuroscience legacy we’ve at Teva, beginning with